Literature DB >> 16282499

Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D.

Niels Smakman1, Diana J M van den Wollenberg, Inne H M Borel Rinkes, Rob C Hoeben, Onno Kranenburg.   

Abstract

Reovirus T3D is an oncolytic agent that preferentially targets tumor cells expressing an activated Ras oncogene. Ras signaling interferes with the cellular stress response that inhibits translation of reovirus RNAs. Murine C26 colorectal carcinoma cells express a mutant KrasD12 gene. Reovirus T3D efficiently kills C26 cells, but not C26 cells in which the KrasD12 mRNA is stably repressed by expression of KrasD12-directed short-hairpin RNAs. Surprisingly, neither reovirus T3D protein synthesis nor T3D virus yields were suppressed by deletion of KrasD12. Rather, reovirus-induced tumor cell apoptosis was completely abrogated as a result of Kras knockdown. We conclude that sensitization of C26 tumor cells to reovirus-induced apoptosis underlies the Ras dependency of reovirus T3D oncolysis.

Entities:  

Mesh:

Year:  2005        PMID: 16282499      PMCID: PMC1287595          DOI: 10.1128/JVI.79.23.14981-14985.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

Review 1.  Gene-specific regulation by general translation factors.

Authors:  Thomas E Dever
Journal:  Cell       Date:  2002-02-22       Impact factor: 41.582

2.  Reovirus-induced apoptosis is mediated by TRAIL.

Authors:  P Clarke; S M Meintzer; S Gibson; C Widmann; T P Garrington; G L Johnson; K L Tyler
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Oncolytic reovirus against ovarian and colon cancer.

Authors:  Kensuke Hirasawa; Sandra G Nishikawa; Kara L Norman; Tommy Alain; Anna Kossakowska; Patrick W K Lee
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

4.  Reovirus oncolysis of human breast cancer.

Authors:  Kara L Norman; Matthew C Coffey; Kensuke Hirasawa; Douglas J Demetrick; Sandra G Nishikawa; Lisa M DiFrancesco; James E Strong; Patrick W K Lee
Journal:  Hum Gene Ther       Date:  2002-03-20       Impact factor: 5.695

5.  Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells.

Authors:  Jan D Lünemann; Sonia Waiczies; Stefan Ehrlich; Uwe Wendling; Bibiane Seeger; Thomas Kamradt; Frauke Zipp
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

6.  The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus.

Authors:  J E Strong; M C Coffey; D Tang; P Sabinin; P W Lee
Journal:  EMBO J       Date:  1998-06-15       Impact factor: 11.598

7.  Proliferation of IL-6-independent multiple myeloma does not require the activity of extracellular signal-regulated kinases (ERK1/2).

Authors:  Bin Zhang; Robert G Fenton
Journal:  J Cell Physiol       Date:  2002-10       Impact factor: 6.384

8.  Selective reovirus killing of bladder cancer in a co-culture spheroid model.

Authors:  Ruhangiz T Kilani; Yahya Tamimi; Erich G Hanel; Kevin K Wong; Shahzeer Karmali; Patrick W K Lee; Ronald B Moore
Journal:  Virus Res       Date:  2003-05       Impact factor: 3.303

Review 9.  Reovirus-induced apoptosis: A minireview.

Authors:  P Clarke; K L Tyler
Journal:  Apoptosis       Date:  2003-03       Impact factor: 4.677

10.  Systemic reovirus therapy of metastatic cancer in immune-competent mice.

Authors:  Kensuke Hirasawa; Sandra G Nishikawa; Kara L Norman; Matthew C Coffey; Bradley G Thompson; Chang-Soon Yoon; David M Waisman; Patrick W K Lee
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

View more
  20 in total

1.  Reovirus variants with mutations in genome segments S1 and L2 exhibit enhanced virion infectivity and superior oncolysis.

Authors:  Maya Shmulevitz; Shashi A Gujar; Dae-Gyun Ahn; Adil Mohamed; Patrick W K Lee
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  Replicating reoviruses with a transgene replacing the codons for the head domain of the viral spike.

Authors:  D J M van den Wollenberg; I J C Dautzenberg; W Ros; A D Lipińska; S K van den Hengel; R C Hoeben
Journal:  Gene Ther       Date:  2015-01-15       Impact factor: 5.250

3.  Reduction of virion-associated σ1 fibers on oncolytic reovirus variants promotes adaptation toward tumorigenic cells.

Authors:  Adil Mohamed; Carmit Teicher; Sarah Haefliger; Maya Shmulevitz
Journal:  J Virol       Date:  2015-02-04       Impact factor: 5.103

Review 4.  Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.

Authors:  Zineb Belcaid; Martine L M Lamfers; Victor W van Beusechem; Rob C Hoeben
Journal:  Hum Gene Ther       Date:  2014-09-17       Impact factor: 5.695

Review 5.  Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.

Authors:  Jun Gong; Esha Sachdev; Alain C Mita; Monica M Mita
Journal:  World J Methodol       Date:  2016-03-26

6.  Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.

Authors:  F Errington; C L White; K R Twigger; A Rose; K Scott; L Steele; L J Ilett; R Prestwich; H S Pandha; M Coffey; P Selby; R Vile; K J Harrington; A A Melcher
Journal:  Gene Ther       Date:  2008-04-10       Impact factor: 5.250

Review 7.  Targeting cancer-initiating cells with oncolytic viruses.

Authors:  Timothy P Cripe; Pin-Yi Wang; Paola Marcato; Yonatan Y Mahller; Patrick Wk Lee
Journal:  Mol Ther       Date:  2009-08-11       Impact factor: 11.454

Review 8.  Oncolytic virus therapy for cancer.

Authors:  Joe Goldufsky; Shanthi Sivendran; Sara Harcharik; Michael Pan; Sebastian Bernardo; Richard H Stern; Philip Friedlander; Carl E Ruby; Yvonne Saenger; Howard L Kaufman
Journal:  Oncolytic Virother       Date:  2013-09-23

9.  Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A.

Authors:  Diana J M van den Wollenberg; Iris J C Dautzenberg; Sanne K van den Hengel; Steve J Cramer; Raoul J de Groot; Rob C Hoeben
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

10.  Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.

Authors:  Katie Twigger; Victoria Roulstone; Joan Kyula; Eleni M Karapanagiotou; Konstantinos N Syrigos; Richard Morgan; Christine White; Shreerang Bhide; Gerard Nuovo; Matt Coffey; Brad Thompson; Adel Jebar; Fiona Errington; Alan A Melcher; Richard G Vile; Hardev S Pandha; Kevin J Harrington
Journal:  BMC Cancer       Date:  2012-08-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.